SCHEMBL18202876

SCHEMBL18202876

Nc1nc2ccnc(-c3cn[nH]c3)n2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 7/20 0.38
▸ TNK2 Q07912 1/20 0.37
▸ NUDT1 P36639 1/20 0.37
▸ JAK2 O60674 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ LRRK2 Q5S007 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MAPK8 P45983 1/20 0.35
▸ MTOR P42345 2/20 0.35
▸ AURKA O14965 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ INCENP Q9NQS7 1/20 0.35
▸ TPX2 Q9ULW0 1/20 0.35
▸ AKT1 P31749 1/20 0.34
▸ AKT2 P31751 1/20 0.34
▸ CHEK2 O96017 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10594663 0.77 NUDT1 (0.41) NUDT1JAK2KDM4EALDH1A1JAK1
SCHEMBL3306356 0.77 NUDT1 (0.57) TNK2NUDT1KDM4EALDH1A1JAK1
SCHEMBL25646677 0.76 LRRK2 (0.40) NUDT1LRRK2JAK1MTORPDE10A
SCHEMBL3599442 0.75 NUDT1 (0.63) CHEK1NUDT1JAK1AKT1AKT2
SCHEMBL10594458 0.75 KDM4E (0.58) NUDT1KDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL2256835 0.75 POLB (0.42) NUDT1KDM4EALDH1A1JAK1NPC1
SCHEMBL3584146 0.74 JAK1 (0.60) JAK2KDM4EALDH1A1JAK1SMN1; SMN2
SCHEMBL3297508 0.74 NUDT1 (0.39) TNK2NUDT1JAK2KDM4EALDH1A1
SCHEMBL10856202 0.72 NUDT1 (0.38) NUDT1JAK2KDM4EALDH1A1JAK1
SCHEMBL10594383 0.72 NUDT1 (0.48) NUDT1KDM4EALDH1A1JAK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022119-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2026-01-22 — — US disclosed
US-12466828-B2 Bicyclic amines as CDK2 inhibitors INCYTE CORPORATION (US) 2025-11-11 — — US disclosed
US-20240174664-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2024-05-30 — — US disclosed
EP-3290418-B1 JANUS KINASE (JAK) INHIBITORS WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) 2019-05-15 — — EP disclosed
US-10174036-B2 Substituted pyrazoles as JAK inhibitors Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2019-01-08 — — US disclosed
US-10174036-B2 Substituted pyrazoles as JAK inhibitors Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2019-01-08 — — US disclosed
US-20180179209-A1 JAK INHIBITORS Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2018-06-28 — — US disclosed
US-20180179209-A1 JAK INHIBITORS Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2018-06-28 — — US disclosed
US-20180179209-A1 JAK INHIBITORS Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2018-06-28 — — US disclosed
EP-3290418-A1 JAK INHIBITORS Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2018-03-07 — — EP disclosed
WO-2016173484-A1 JAK INHIBITORS 南京明德新药研发股份有限公司 2016-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174036-B2 Substituted pyrazoles as JAK inhibitors JAK1, JAK2, JAK3 CHEK1 405/4885TNK2 844/4885NUDT1 2706/4885
US-20260022119-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CCNA1, CDK1, CCNE1 CHEK1 211/4885TNK2 309/4885NUDT1 1340/4885
US-20180179209-A1 JAK INHIBITORS JAK2, JAK1, JAK3 CHEK1 448/4885TNK2 628/4885NUDT1 3577/4885
US-20240174664-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CDK2, CDK1, CCNI CHEK1 64/4885TNK2 96/4885NUDT1 715/4885
US-12466828-B2 Bicyclic amines as CDK2 inhibitors CDK2, CDK1, CCNI CHEK1 64/4885TNK2 96/4885NUDT1 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback